Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses

Alfred Chung, MD, Gregory P. Kaufman, MD, Surbhi Sidana, MD, David Iberri, MD, Erik Eckhert, MD MS, Stanley Schrier, MD, Richard Lafayette, MD, Sally Arai, MD, Ronald Witteles, MD, Michaela Liedtke, MD

Blood (2019) 134 (Supplement_1): 1884.

https://doi.org/10.1182/blood-2019-124981

Published: 2019

Journal Articles

Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis

Alfred Chung, MD, Gregory P. Kaufman, MD, Surbhi Sidana, MD, Erik Eckhert, MD MS, Stanley Schrier, MD, Sally Arai, MD, Richard Lafayette, MD, Ronald Witteles, MD, Michaela Liedtke, MD

Blood (2019) 134 (Supplement_1): 1828.

https://doi.org/10.1182/blood-2019-122152

Published: 2019

Journal Articles

Graded Cardiac Response Correlates with Relapse and Survival in AL Amyloidosis

Erik Keith Eckhert, MD MS, Ronald Witteles, MD, Gregory Kaufman, MD, Richard Lafayette, MD, Sally Arai, MD, Stanley Schrier, MD, Michelle O'Shaughnessy, MB BCh MS, Michaela Liedtke, MD

Blood (2018) 132 (Supplement 1): 4486.

https://doi.org/10.1182/blood-2018-99-113577

Published: 2018

Journal Articles

RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9

James Y Chen, MD PhD, Kelly Marie McKenna, BS, Timothy S Choi, BS, Jiaqi Duan, MS, Lynette Brown, MSc, Jennifer J Stewart, PhD, Kavitha Sompalli, MS, Paresh Vyas, Stanley Schrier, MD, Ravindra Majeti, MD PhD, Irving L Weissman, MD, Kyle Elrod, BS, Mark Ping Chao, MD PhD, Chris H Takimoto, MD PhD, Jie Liu, PhD MD, Jens-Peter Volkmer, MD

Blood (2018) 132 (Supplement 1): 2327.

https://doi.org/10.1182/blood-2018-99-115674

Published: 2018

Journal Articles

Hematologic Responses and Cardiac Organ Improvement in Patients with Heavily Pretreated Cardiac Immunoglobulin Light Chain (AL) Amyloidosis Receiving Daratumumab

Gregory Kaufman, MD, Ronald Witteles, MD, Matthew Wheeler, MD, Patricia Ulloa, RN, Marie Lugtu, RN, Sally Arai, MD, Stanley Schrier, MD, Richard Lafayette, MD, Michaela Liedtke, MD

Blood (2016) 128 (22): 4525.

https://doi.org/10.1182/blood.V128.22.4525.4525

Published: 2016

Journal Articles

AL Amyloidosis: Prognosis of Cardiac Involvement Reconsidered.

Wesley Witteles, MD, Ronald Witteles, MD, Sally Arai, MD, Richard Lafayette, MD, Stanley Schrier, MD

Blood (2009) 114 (22): 4872.

https://doi.org/10.1182/blood.V114.22.4872.4872

Published: 2009

Journal Articles

Alterations of Granulopoiesis Following Chemotherapy

Peter Greenberg, Ine Bax, Beth Mara, Stanley Schrier

Blood (1974) 44 (3): 375–383.

https://doi.org/10.1182/blood.V44.3.375.375

Published: 1974

NARROW

Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses

Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis

Graded Cardiac Response Correlates with Relapse and Survival in AL Amyloidosis

RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9

Hematologic Responses and Cardiac Organ Improvement in Patients with Heavily Pretreated Cardiac Immunoglobulin Light Chain (AL) Amyloidosis Receiving Daratumumab

AL Amyloidosis: Prognosis of Cardiac Involvement Reconsidered.

Alterations of Granulopoiesis Following Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses

Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis

Graded Cardiac Response Correlates with Relapse and Survival in AL Amyloidosis

RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9

Hematologic Responses and Cardiac Organ Improvement in Patients with Heavily Pretreated Cardiac Immunoglobulin Light Chain (AL) Amyloidosis Receiving Daratumumab

AL Amyloidosis: Prognosis of Cardiac Involvement Reconsidered.

Alterations of Granulopoiesis Following Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only